Secondary mutations in t(4;11) leukemia patients

Leukemia

Volumn 27, Issue 6, 2013, Pages 1425-1427

  Prelle, C ^a   Bursen, A ^a   Dingermann, T ^a   Marschalek, R ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; GENOMIC DNA;

ACUTE LEUKEMIA; CANCER INCIDENCE; CANCER PATIENT; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOMICS; HUMAN; LETTER; MAJOR CLINICAL STUDY; MISSENSE MUTATION; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL;

CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; FMS-LIKE TYROSINE KINASE 3; GENES, RAS; HUMANS; LEUKEMIA; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; TRANSLOCATION, GENETIC;

EID: 84878938198     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.365     Document Type: Letter

References (15)

1. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J et al. New insights into the MLL recombinome of acute leukemias. Leukemia 2009; 23: 1490-1499.
2. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011; 152: 141-154.
3. Bardini M, Spinelli R, Bungaro S, Mangano E, Corral L, Cifola I et al. DNA copynumber abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia 2010; 24: 169-176.
4. Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, Masterson M et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer 1998; 21: 270-275. (Pubitemid 28136447)
5. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004; 103: 1085-1088. (Pubitemid 38129575)
6. Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer 2006; 106: 950-956.
7. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665. (Pubitemid 37328820)
8. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004; 103: 3544-3546. (Pubitemid 38525690)
9. Furuichi Y, Goi K, Inukai T, Sato H, Nemoto A, Takahashi K et al. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. Cancer Res 2007; 67: 9852-9861. (Pubitemid 47621233)
10. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2007; 110: 2774-2775. (Pubitemid 47523212)
11. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009; 36: 326-339.
12. Ng MH, Ng RK, Kong CT, Jin DY, Chan LC. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. Exp Hematol 2010; 38: 481-488.
13. Moriya K, Suzuki M, Watanabe Y, Takahashi T, Aoki Y, Uchiyama T et al. Development of a multi-step leukemogenesis model of MLL-rearranged leukemia using humanized mice. PLoS One 2012; 7: e37892.
14. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2207; 21: 43-48.
15. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105: 812-820. (Pubitemid 40070769)